<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Management of hemorrhage in gynecologic surgery</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Management of hemorrhage in gynecologic surgery</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Management of hemorrhage in gynecologic surgery</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Authors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">William H Parker, MD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Willis H Wagner, MD</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Howard T Sharp, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Kristen Eckler, MD, FACOG</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Jun 02, 2022.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Intraoperative hemorrhage is generally defined as blood loss exceeding 1000 mL or requiring a blood transfusion [<a href="#rid1">1</a>]. Massive hemorrhage refers to acute blood loss of more than 25 percent of a patient's blood volume or bleeding that requires emergency intervention to save the patient's life [<a href="#rid2">2</a>].</p><p>Severe postoperative anemia impacts perioperative morbidity and mortality [<a href="#rid3">3</a>]. This was illustrated in a study of hospitalized patients who refused blood transfusion for religious reasons: mortality increased as hemoglobin levels fell below 7 g/dL.</p><p>This topic review will discuss management of hemorrhage in gynecologic surgery. Surgical technique for specific procedures, incisional bleeding, and management of other complications of gynecologic surgery are reviewed separately (see  <a class="medical medical_review" href="/d/html/1.html" rel="external">"Complications of abdominal surgical incisions"</a> and  <a class="medical medical_review" href="/d/html/3289.html" rel="external">"Complications of gynecologic surgery"</a>). (Also see individual gynecologic surgery topic reviews.)</p><p>In this topic, when discussing study results, we will use the terms "woman/en" or "patient(s)" as they are used in the studies presented. However, we encourage the reader to consider the specific counseling and treatment needs of transgender and gender diverse individuals.</p><p class="headingAnchor" id="H2"><span class="h1">PREOPERATIVE EVALUATION</span><span class="headingEndMark"> — </span>Preoperative evaluation with a focus on preventing and preparing for perioperative hemorrhage is discussed below. Preoperative assessment for gynecologic surgery is discussed in full elsewhere. (See  <a class="medical medical_review" href="/d/html/3301.html" rel="external">"Overview of preoperative evaluation and preparation for gynecologic surgery"</a>.)</p><p class="headingAnchor" id="H3"><span class="h2">Medical history</span><span class="headingEndMark"> — </span>Important elements of the history are a personal or family history of prolonged bleeding, transfusion, or persistent anemia. Nongynecologic etiologies of bleeding symptoms may be present. For example, menorrhagia, a common indication for gynecologic surgery, can be a presenting symptom of von Willebrand disease (VWD). (See  <a class="medical medical_review" href="/d/html/1367.html" rel="external">"Approach to the adult with a suspected bleeding disorder"</a>.)</p><p>Further evaluation by a hematologist is warranted if a bleeding disorder is suspected. Timely diagnosis allows for preoperative correction of coagulation defects.</p><p class="headingAnchor" id="H4"><span class="h2">Medication history</span><span class="headingEndMark"> — </span>Prescription, over-the-counter, or alternative medications can act as anticoagulants. Deciding whether to discontinue a medication perioperatively depends upon the risk of bleeding versus the risk of morbidity from a hiatus of medical treatment. Consultation with a patient's primary care provider and an anesthesiologist is appropriate. Perioperative use of medication is discussed separately. (See  <a class="medical medical_review" href="/d/html/4814.html" rel="external">"Perioperative medication management"</a>.)</p><p class="headingAnchor" id="H5"><span class="h2">Laboratory evaluation</span></p><p class="bulletIndent1"><span class="glyph">●</span>A baseline hematocrit (Hct) is useful  (<a class="graphic graphic_table graphicRef75939" href="/d/graphic/75939.html" rel="external">table 1</a>) [<a href="#rid4">4</a>]. If a patient has abnormal uterine bleeding or another cause for anemia, testing should be performed early in the surgical planning process to allow time for correction of anemia. (See  <a class="medical medical_review" href="/d/html/4816.html" rel="external">"Preoperative medical evaluation of the healthy adult patient"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>A blood sample for ABO and Rh typing and antibody screen is typically sent to the blood bank for patients undergoing surgery in which the expected blood loss is greater than minimal; if significant bleeding is anticipated, it is prudent to prepare two to four units of donor blood by crossmatching with the patient's serum with the donor red cells to check for incompatibility. (See  <a class="medical medical_review" href="/d/html/7953.html" rel="external">"Pretransfusion testing for red blood cell transfusion"</a>.)</p><p></p><p class="bulletIndent1">Questions have been raised regarding whether routine preoperative type and screen testing is cost effective (versus testing intraoperatively if transfusion is indicated). Observational studies in women undergoing gynecologic surgery have reported that transfusions were infrequent and did not require initiation of transfusion in less than 30 minutes [<a href="#rid5">5,6</a>]. Thus, any proposal for intraoperative testing alone would require reliable delivery of blood to the patient within 30 minutes of onset of hemorrhage. Also, provisions would need to be made for patients who require initiation of transfusion in less than 30 minutes (eg, massive hemorrhage or comorbidities) or in whom compatibility testing is time-consuming (eg, antibodies). Further study is required before such a proposal is implemented.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Routine tests of hemostasis (prothrombin time [PT], activated partial thromboplastin time [aPTT], platelet count) are NOT necessary unless the patient has a known bleeding diathesis, an illness associated with bleeding tendency, or takes a medication that may cause anticoagulation  (<a class="graphic graphic_table graphicRef75939" href="/d/graphic/75939.html" rel="external">table 1</a>) [<a href="#rid4">4</a>]. (See  <a class="medical medical_review" href="/d/html/1315.html" rel="external">"Preoperative assessment of bleeding risk"</a>.)</p><p></p><p class="headingAnchor" id="H6"><span class="h1">PREPARATION FOR SURGERY</span><span class="headingEndMark"> — </span>Discussion of possible blood transfusion is part of the informed consent process. A patient's concerns about transmission of blood-borne pathogens should be discussed in the context of current incidence reported by blood banks  (<a class="graphic graphic_table graphicRef69661" href="/d/graphic/69661.html" rel="external">table 2</a>). (See  <a class="medical medical_review" href="/d/html/3301.html" rel="external">"Overview of preoperative evaluation and preparation for gynecologic surgery"</a> and  <a class="medical medical_review" href="/d/html/7946.html" rel="external">"Blood donor screening: Laboratory testing"</a>.)</p><p>Women with blood transfusion incompatibilities or religious beliefs that preclude allogeneic blood transfusion should be identified prior to surgery. (See  <a class="medical medical_review" href="/d/html/7927.html" rel="external">"Approach to the patient who declines blood transfusion"</a> and  <a class="medical medical_review" href="/d/html/7954.html" rel="external">"Red blood cell (RBC) transfusion in individuals with serologic complexity"</a>.)</p><p>In addition to careful surgical technique, strategies to avoid allogeneic blood product transfusion include correction of anemia, autologous blood donation, cell salvage, and hemodilution.</p><p class="headingAnchor" id="H7"><span class="h2">Correction of anemia</span><span class="headingEndMark"> — </span>Women planning gynecologic surgery to treat bleeding issues have typically declined or failed medical therapy. However, most women will accept a short course of preoperative therapy with the goal of increasing Hct and, thereby, avoiding the need for blood transfusion. Iron deficiency anemia associated with menorrhagia or dietary deficiency is the most common cause of anemia in the gynecologic population [<a href="#rid7">7</a>]. Strategies to correct anemia preoperatively are used in the order listed below:</p><p class="bulletIndent1"><span class="glyph">●</span>Iron supplementation – In surgical patients, intravenous iron alone increased hemoglobin levels by 1 to 2 g in as little as one week and a review of 14 studies reported a clinically and statistically significant increase in hemoglobin in patients treated with intravenous iron alone [<a href="#rid8">8,9</a>]. Oral option is a good option in nonurgent cases. (See  <a class="medical medical_review" href="/d/html/7148.html" rel="external">"Treatment of iron deficiency anemia in adults"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Medical treatment of abnormal uterine bleeding. (See  <a class="medical medical_review" href="/d/html/5440.html" rel="external">"Causes of female genital tract bleeding"</a> and  <a class="medical medical_review" href="/d/html/5476.html" rel="external">"Abnormal uterine bleeding in nonpregnant reproductive-age patients: Management"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Erythropoiesis-stimulating agents (recombinant human erythropoietin [rHuEPO] and <a class="drug drug_general" data-topicid="8662" href="/d/drug information/8662.html" rel="external">darbepoetin alfa</a>) – Data from randomized trials in gynecologic [<a href="#rid10">10,11</a>], orthopedic [<a href="#rid12">12-15</a>], and cardiac surgery [<a href="#rid16">16</a>] suggest preoperative rHuEPO reduces risk of allogeneic transfusion. For women who do not tolerate, or do not wish to take, GnRH-agonists, we have found epoetin particularly useful. However, preoperative use in gynecologic surgery is not well-established and insurance reimbursement is variable.</p><p></p><p class="bulletIndent1">While safety concerns have been raised about the use of rHuEPO, these risks were confined to repetitive use in cancer patients receiving chemotherapy. The US Food and Drug Administration (FDA) has issued a warning based on reports that erythropoiesis-stimulating agents are associated with serious cardio- and thrombovascular events and more rapid tumor progression and increased mortality in cancer patients (including cervical cancer) [<a href="#rid17">17</a>].</p><p></p><p class="bulletIndent1">However, there may be a role for preoperative EPO to correct anemia in patients who would refuse allogeneic transfusion are too anemic to qualify for autologous blood donation. (See  <a class="medical medical_review" href="/d/html/8383.html" rel="external">"Introduction to recombinant hematopoietic growth factors"</a> and  <a class="medical medical_review" href="/d/html/7930.html" rel="external">"Surgical blood conservation: Preoperative autologous blood donation", section on 'Erythropoietin (rarely indicated)'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Preoperative transfusion may be required for patients who become unstable or who continue to bleed heavily before definitive therapy can be performed. We agree with guidelines which emphasize that the decision to transfuse is based not only on hemoglobin level, but also includes individual patient characteristics and symptoms. (See  <a class="medical medical_review" href="/d/html/7948.html" rel="external">"Indications and hemoglobin thresholds for RBC transfusion in adults", section on 'Overview of our approach'</a>.)</p><p></p><p class="headingAnchor" id="H8"><span class="h2">Autologous transfusion methods</span><span class="headingEndMark"> — </span>In addition to correction of anemia, preoperative preparations can be made to use autologous blood in the event a transfusion is necessary. Methods of autologous transfusion are listed below:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Autologous blood donation</strong> – A patient scheduled for surgery who is not anemic may bank one or more units of her own blood. (See  <a class="medical medical_review" href="/d/html/7930.html" rel="external">"Surgical blood conservation: Preoperative autologous blood donation"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Intraoperative and postoperative blood salvage</strong> – Blood that is shed during or after surgery is retrieved, processed, and returned to the patient. (See  <a class="medical medical_review" href="/d/html/7937.html" rel="external">"Surgical blood conservation: Intraoperative blood salvage"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Acute normovolemic (isovolemic) hemodilution</strong> – Blood is removed from a patient, either immediately before or shortly after induction of anesthesia, with isovolemia maintained using crystalloid and/or colloid replacement. The blood withdrawn is anticoagulated and is reinfused into the patient as needed during, or after, the surgical procedure. (See  <a class="medical medical_review" href="/d/html/7936.html" rel="external">"Surgical blood conservation: Acute normovolemic hemodilution"</a>.)</p><p></p><p>A systematic review of high- and low-quality data regarding methods of avoiding allogeneic blood transfusion found that reports are variable and no consensus could be reached regarding which method is more cost effective and acceptable to patients [<a href="#rid18">18</a>].</p><p>In our practice, we have used blood salvage (eg, Cell Saver) effectively during myomectomy and hysterectomy [<a href="#rid19">19</a>]. The device suctions blood from the operative field, mixes it with heparinized <a class="drug drug_general" data-topicid="9929" href="/d/drug information/9929.html" rel="external">saline</a> and stores the blood in a canister. If the patient requires blood re-infusion, the stored blood is washed with saline, filtered, centrifuged to a hematocrit of approximately 50 percent, and transfused into the patient. </p><p>Use of intraoperative cell salvage avoids the need for preoperative autologous blood donation and homologous (non-autologous, allogeneic) blood transfusion can often be avoided [<a href="#rid20">20</a>]. Use of the cell-saver avoids the risks of transmission of infectious disease and eliminates transfusion reactions. In addition, recent evidence shows that storage of blood products leads to a progressive decrease in the quality of stored blood and an increase in inflammatory mediators [<a href="#rid21">21</a>]. This would affect patients receiving either autologous or homologous blood.</p><p>The cost of using a blood salvage compared with donation of autologous blood has not been studied for gynecologic procedures. Most hospitals charge a minimal fee for having the blood salvage equipment available "on-call" and charge additionally if it is used. </p><p class="headingAnchor" id="H1978420098"><span class="h2">Prophylactic tranexamic acid</span><span class="headingEndMark"> — </span>Prophylactic administration of TXA, an anti-fibrinolytic, has been associated with reduced intraoperative blood loss in both obstetric and gynecologic surgery [<a href="#rid22">22-25</a>]. Discussion of dosing, timing, and supporting data is presented in related content. (See  <a class="medical medical_review" href="/d/html/3301.html" rel="external">"Overview of preoperative evaluation and preparation for gynecologic surgery", section on 'Prophylactic tranexamic acid'</a>.)</p><p class="headingAnchor" id="H9"><span class="h1">MANAGEMENT OF INTRAOPERATIVE BLEEDING</span><span class="headingEndMark"> — </span>As complications cannot be completely avoided, the gynecologic surgical team should be prepared to handle intraoperative hemorrhage. In the obstetric literature, studies of simulation-based teaching of management of postpartum hemorrhage have demonstrated that this approach identifies important deficiencies in clinician knowledge and performance [<a href="#rid26">26,27</a>]. Similarly, simulation in gynecologic surgery has been shown to reduce time to intervention during a crisis and improve surgical skills [<a href="#rid28">28-30</a>]. We employ the following techniques in the order of presentation.</p><p class="headingAnchor" id="H10"><span class="h2">Apply pressure</span><span class="headingEndMark"> — </span>At the onset of intraoperative hemorrhage, apply pressure to the bleeding area. This helps to control acute bleeding and allows a moment to alert the rest of the operating room team that excessive bleeding is occurring. Immediate and ongoing communication with all members of the surgical team (anesthesiologists, nurses, scrub technicians) is essential to an efficient and effective response to intraoperative hemorrhage.</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Laparotomy</strong> – Apply immediate pressure with a finger or sponge stick. If localized pressure does not control bleeding, firmly place damp laparotomy pads at the bleeding site. Apply pressure for 10 to 15 minutes, and observe the packs to confirm that bleeding has stopped.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Laparoscopy</strong> – Apply an atraumatic laparoscopic grasper to the site of bleeding. For larger bleeding sites, insert 4x8 gauze sponges through a 10 mm port and hold pressure against the bleeding area. Large vessel lacerations (ie, due to trocar insertion) cannot generally be repaired laparoscopically, and thus, make a vertical midline incision to allow surgical access to the great vessels. Tamponade can then be applied directly as described above.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Vaginal surgery</strong> – Apply immediate pressure with a finger or sponge stick. If bleeding continues, place a pack of damp pads or sponges in the vagina. Slowly remove the pack to visualize the bleeding vessels. If a vascular pedicle is lost during vaginal surgery, blind clamping or suturing is ill-advised. Laparoscopy can be used to identify and control the bleeding site, with laparotomy reserved for bleeding inaccessible to laparoscopic techniques.</p><p></p><p>While securing hemostasis is critical, techniques must be used carefully in order to avoid tissue necrosis, organ injury, vascular thrombosis, fistula formation, or nerve dysfunction [<a href="#rid31">31</a>]. Once the bleeding area is identified and tamponade applied, identify the ureter and major vessels to avoid inadvertent injuries to these structures. Also, it is generally better to avoid leaving packs in place at venous bleeding sites due to risk of venous stasis and thrombosis.</p><p>In some cases, it is best to apply continued pressure while waiting for a vascular or general surgeon, a gynecologic oncologist, or another gynecologist. Applying pressure to a large vessel (ie, aorta or common iliac) should be reserved for situations in which direct pressure to the bleeding site does not stop or significantly slow the bleeding. Attempts at repair of vessels without experience may worsen the injury, particularly in major retroperitoneal veins.</p><p class="headingAnchor" id="H11"><span class="h2">Identify and control localized bleeding</span><span class="headingEndMark"> — </span>The most common sites of major blood loss in the pelvis (cephalad to caudad) are inferior vena cava, presacral veins, ovarian vessels, common and external iliac vessels, internal iliac vessels, parametrial and paracervical varicosities, the bladder pillars, and posterior bladder.</p><p>To locate bleeding sites from one or more vessels, dissect the pelvic fascia surrounding the source of bleeding, identify vital structures (ie, vessels, viscera), and isolate and ligate the bleeding vessels.</p><p class="headingAnchor" id="H12"><span class="h3">Pelvic dissection</span><span class="headingEndMark"> — </span>The vascular structures of the reproductive tract are contained within the tissues that surround the pelvic viscera (ie, the paravesical, pararectal, vesicovaginal, and rectovaginal spaces). Development of the appropriate space will often allow control of bleeding sites while avoiding trauma to important pelvic structures [<a href="#rid31">31</a>].</p><p>Care should be taken during dissection, as the walls of the major veins are delicate and injury can cause brisk bleeding. Also, blunt dissection along the common iliac vein, inferior vena cava, pelvic sidewall or the presacral area can avulse small tributaries from larger veins with resultant high volume bleeding.</p><p>Surgeons who do not perform radical surgery may be less familiar with the paravesical and pararectal spaces  (<a class="graphic graphic_figure graphicRef56539" href="/d/graphic/56539.html" rel="external">figure 1</a>). The paravesical space is bounded laterally by the external iliac vessels and medially by the obliterated hypogastric artery. Dissection of this space exposes the lateral portions of the bladder, vagina and rectum. (See  <a class="medical medical_review" href="/d/html/3303.html" rel="external">"Radical hysterectomy", section on 'Operative technique'</a>.)</p><p>The pararectal space is bounded laterally by the internal iliac artery and medially by the ureter, and can be entered by incision of the pelvic peritoneum (and preferably the round ligament) lateral to the iliac vessels. Separation of the vessels and the ureter and dissection posteriorly and slightly medially exposes the proximal pelvic ureter, the internal iliac vessels and the rectum.</p><p class="headingAnchor" id="H13"><span class="h3">Retroperitoneal bleeding</span><span class="headingEndMark"> — </span>If bleeding occurs, and the retroperitoneum is not open or the bleeding is behind the ovarian pedicle, apply direct pressure to the area of bleeding. If bleeding continues, a fast, bloodless approach to exposing this area is to open the peritoneum over the paracolic gutter and mobilize the colon medially. If the peritoneum is already open, then the bleeding source is identified and managed as outlined above.</p><p class="headingAnchor" id="H14"><span class="h3">Ligation</span><span class="headingEndMark"> — </span>Isolate vessels prior to ligation. Placing sutures, clips, or coagulating multiple layer of tissue may injure surrounding structures.</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Small vessels</strong> – Bleeding from small vessels may be controlled with coagulation, suture, or surgical clips.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Large vessels</strong> – The aorta, vena cava, and common and external iliac vessels perfuse the extremities. Repair of these vessels is best performed by a vascular surgeon. In general, these vessels are repaired by compressing the vessel above and below the injury with vascular clamps and suturing the defect with a running 4-0 to 6-0 monofilament suture on a cardiovascular needle.</p><p></p><p class="bulletIndent1">The extensive arterial collateral circulation in the peripheral pelvis allows ligation of most other large vessels in a nonirradiated pelvis [<a href="#rid31">31</a>]. Coagulation is not adequate for larger vessels and clips may either fall off or cut into a vessel larger than the clip, thereby enlarging the defect. Placing multiple clips also makes it difficult to isolate and identify the bleeding site.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Large veins</strong> – Venous bleeding can be difficult to control due to the relatively high volume of blood flowing through fragile, irregular veins. Gentle pressure with sponge sticks on either side of the venous injury is the most useful method to minimize blood loss.</p><p></p><p class="bulletIndent1">In addition, the placement of hemoclips will often control venous bleeding. However, application of hemoclips to a "peg hole defect" (avulsion of the small veins that enter the anterior surface of the common iliac vein and the inferior vena cava) can reduce the caliber of the lumen and lead to coagulation and thrombosis.</p><p></p><p class="headingAnchor" id="H15"><span class="h2">Manage diffuse bleeding</span><span class="headingEndMark"> — </span>There are several clinically important causes of diffuse bleeding, each of which must be addressed differently. Assess the volume of bleeding and whether there is flow at all operative surfaces (and intravenous line sites) or it is concentrated in one or more areas.</p><p>Alternatively, diffuse low-volume bleeding that is concentrated in several small areas (eg, sites of prior dissection of adhesions) is likely from small venous sources and may be amenable to the use of topical hemostatic agents. When brisk diffuse bleeding arises suddenly in the presacral area, laceration of the presacral vessels should be suspected and immediately addressed.</p><p class="headingAnchor" id="H16"><span class="h3">Topical hemostatic agents</span><span class="headingEndMark"> — </span>Small areas of low-volume bleeding can be treated with topical hemostatic agents  (<a class="graphic graphic_table graphicRef71852" href="/d/graphic/71852.html" rel="external">table 3</a>) [<a href="#rid32">32,33</a>]. Investigation of these agents has focused on vascular, cardiac, and hepatic surgery [<a href="#rid34">34,35</a>]. There are few high-quality data regarding treatment efficacy or use in gynecologic surgery [<a href="#rid36">36</a>]. Thus, choices are made based on surgeon preference, availability, and cost-effectiveness  (<a class="graphic graphic_table graphicRef71852" href="/d/graphic/71852.html" rel="external">table 3</a>) [<a href="#rid37">37</a>]. A detailed discussion of all topical hemostatic agents can be found in separate content. (See  <a class="medical medical_review" href="/d/html/15069.html" rel="external">"Overview of topical hemostatic agents and tissue adhesives"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Our approach</strong> – For gynecologic procedures, the authors typically use gelatin soaked with <a class="drug drug_general" data-topicid="10285" href="/d/drug information/10285.html" rel="external">topical thrombin</a> for localized suture line bleeding (discussed below under topical agents). In settings of diffuse low pressure bleeding, spray thrombin can achieve hemostasis. Use of a combination hemostatic matrix (gelatin granules combined with human thrombin) can also be applied. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Physical agents</strong> – These products require an intact coagulation cascade [<a href="#rid38">38</a>]. The physical agent (cellulose, gelatin, starch, or collagen) is placed at the site of bleeding and activates the extrinsic clotting cascade  (<a class="graphic graphic_figure graphicRef69920" href="/d/graphic/69920.html" rel="external">figure 2</a>). </p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Gelatin</strong> – Gelatin (eg, Gelfoam) is available in sponge or powder form [<a href="#rid39">39,40</a>]. The sponge form can be cut into any shape to facilitate application. Gelatin sponges are rigid when dry, but are pliable when moist and can be passed through laparoscopic ports. Pressure is applied for several minutes after application and the sponge is left in place. Gelatin is completely absorbed after four to six weeks with little tissue reaction or scarring.</p><p></p><p class="bulletIndent2">Disadvantages of gelatin include: increased incidence of infection, granuloma, and fibrosis formation, as well as potential disruption of the clot if the sponge is removed [<a href="#rid39">39,41</a>].</p><p></p><p class="bulletIndent2">There are no data regarding use of topical gelatin for hemostasis in gynecologic surgery.</p><p></p><p class="bulletIndent2">Although it is common practice to apply <a class="drug drug_general" data-topicid="10285" href="/d/drug information/10285.html" rel="external">topical thrombin</a> to gelatin matrix, in attempt to increase hemostasis, there are no data to support this [<a href="#rid32">32</a>].</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><a class="drug drug_general" data-topicid="10083" href="/d/drug information/10083.html" rel="external">Oxidized regenerated cellulose</a><strong> (ORC)</strong> – ORC (eg, Surgicel) is supplied as a mesh and can be applied dry directly to bleeding areas. ORC is pliable and can be rolled and passed easily through laparoscopic trocars. It requires a blood-free field to be effective. ORC takes 14 days to be fully absorbed [<a href="#rid41">41</a>]. Fibrillar is loosely woven ORC, having a consistency similar to cotton. It can be applied to irregular surfaces and hard-to-reach areas, and layers can be peeled off to conform to the wound surface. Both products can coagulate even in a bloody surgical field.</p><p></p><p class="bulletIndent2">ORC also has bactericidal activity against a wide range of gram-positive and negative organisms [<a href="#rid42">42</a>]. However, excessive use of ORC may facilitate infection or formation of adhesions.</p><p></p><p class="bulletIndent2">Successful use of ORC to control bleeding from small uterine perforations [<a href="#rid43">43</a>] and tubal hemorrhage [<a href="#rid44">44</a>] has been reported in small case series.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Microfibrillar collagen (MC)</strong> – MC (eg, Avitene) is an absorbable acid salt obtained from bovine collagen. MC is applied in powder form directly to the bleeding site using a dry, smooth forceps. MC is fully absorbed within three months. Although MC has low antigenicity, it may induce local edema. There is one case report of a systemic allergic reaction during a laparoscopic cholecystectomy associated with MC [<a href="#rid45">45</a>].</p><p></p><p class="bulletIndent2">Case reports of MC use report successful results in bleeding from uterine perforation [<a href="#rid46">46</a>] and after hysterectomy [<a href="#rid47">47</a>]; adverse effects noted include severe allergic reaction [<a href="#rid45">45</a>] and granuloma formation [<a href="#rid48">48</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Biologic agents</strong> –<strong> </strong>This category, which includes <a class="drug drug_general" data-topicid="10285" href="/d/drug information/10285.html" rel="external">topical thrombin</a> and fibrin sealant, bypasses the extrinsic pathway and directly activates the common hemostatic pathway  (<a class="graphic graphic_figure graphicRef69920" href="/d/graphic/69920.html" rel="external">figure 2</a>) [<a href="#rid38">38</a>]. </p><p></p><p class="bulletIndent2"><span class="glyph">•</span><a class="drug drug_general" data-topicid="10285" href="/d/drug information/10285.html" rel="external">Topical thrombin</a><strong> (TT)</strong> – Bovine or human thrombin is used [<a href="#rid49">49,50</a>]. Bovine thrombin is associated with anaphylaxis and the development of antibodies which can cross react with human factor V or human thrombin, leading to coagulopathy [<a href="#rid50">50,51</a>]. In addition, there is a risk of infection transmission with human pooled plasma-derived thrombin [<a href="#rid52">52</a>]. The development of recombinant thrombin may obviate these concerns, however, data on its use are still preliminary [<a href="#rid52">52,53</a>]. The adverse effect of TT are discussed in full separately. (See  <a class="medical medical_review" href="/d/html/7938.html" rel="external">"Fibrin sealants", section on 'Complications'</a>.)</p><p></p><p class="bulletIndent2">TT (eg, Thrombogen) can be applied via direct spray with a needle and syringe or in conjunction with a gelatin sponge in the surgical field [<a href="#rid54">54</a>].</p><p></p><p class="bulletIndent2">The use of thrombin has not been widely studied in gynecologic surgery [<a href="#rid55">55</a>].</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Fibrin sealant</strong> – Fibrin sealants (eg, Tisseel) have two components that must be mixed prior the application, one with thrombin and <a class="drug drug_general" data-topicid="9186" href="/d/drug information/9186.html" rel="external">calcium chloride</a> and other with concentrated fibrinogen, factor XIII, fibronectin, and fibrinolysis inhibitor [<a href="#rid41">41</a>]. The mixture can then be directly sprayed onto bleeding sites.</p><p></p><p class="bulletIndent2">Fibrin sealants are used for hemostasis or as a tissue adhesive. This topic is discussed in more detail separately. (See  <a class="medical medical_review" href="/d/html/7938.html" rel="external">"Fibrin sealants", section on 'Fibrinogen'</a>.)</p><p></p><p class="bulletIndent2">There is one case report of transmission of parvovirus after use of a fibrin sealant for hemostasis during a hysterectomy [<a href="#rid56">56</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Combination reparations</strong> – Available combination products include thrombin/gelatin granules and thrombin/collagen  (<a class="graphic graphic_table graphicRef71852" href="/d/graphic/71852.html" rel="external">table 3</a>). Both preparations are supplied in liquid form and applied to the bleeding site; pressure is then held with a damp sponge.</p><p></p><p class="bulletIndent1">Successful reduction in blood loss with use of thrombin/gelatin has been reported in myomectomy and in a patient with a groin wound breakdown following lymphadenectomy [<a href="#rid57">57,58</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Comparing topical agents</strong> – Representative comparative studies in which topical agents were used for small intraoperative bleeding sites are listed below [<a href="#rid34">34</a>]:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>A combined preparation of liquid thrombin and gelatin yielded a significantly higher rate of hemostasis (at 10 minutes after application) compared with a gelatin sponge soaked in bovine TT (88 to 99 versus 57 to 93 percent), according to randomized trials in patient undergoing vascular, spinal, or cardiac surgery [<a href="#rid40">40,59,60</a>].</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>An autologous fibrin sealant (available in Europe, but not in the United States) resulted in a significantly higher rate of hemostasis (at 5 minutes after application) compared with ORC (94 versus 65 percent) in a randomized trial of 69 patients undergoing obstetric, gynecologic, general, vascular, and cardiothoracic surgery [<a href="#rid61">61</a>].</p><p></p><p class="headingAnchor" id="H17"><span class="h3">Presacral bleeding</span><span class="headingEndMark"> — </span>Laceration of the presacral plexus of veins and/or the middle sacral artery can lead to life-threatening hemorrhage. Pressing a sterile steel thumbtack directly into the bone at the bleeding site has been reported to be effective in observational studies [<a href="#rid62">62</a>]. The tack is not removed, and will show up on subsequent radiographs. Topical hemostatic agents, coagulation, clips, and sutures may also control the bleeding [<a href="#rid63">63</a>]. Another measure that has been reported is to excise a piece of the rectus muscle, place it over the site of bleeding, and then weld it to the bleeding site with electrocautery at a high setting (100 Hz) [<a href="#rid64">64</a>]. As a last resort, an umbrella or parachute pack can be placed until the patient is stabilized [<a href="#rid65">65</a>]. </p><p class="headingAnchor" id="H18"><span class="h2">Strategies for persistent bleeding</span></p><p class="headingAnchor" id="H19"><span class="h3">Internal iliac artery ligation</span><span class="headingEndMark"> — </span>After initial attempts to regain hemostasis have not succeeded, the next step is to decrease pelvic blood flow. Bilateral internal iliac (hypogastric) artery ligation (IAL) lowers the pulse pressure of the pelvic vasculature by 85 percent and the rate of blood flow by 50 percent; low pressure systems are more amenable to clot formation [<a href="#rid66">66,67</a>]  (<a class="graphic graphic_figure graphicRef83009" href="/d/graphic/83009.html" rel="external">figure 3</a>).</p><p>IAL may help to avoid emergency hysterectomy. In a retrospective case series of patients with severe obstetric hemorrhage, 8 of 19 patients who underwent IAL did not undergo a subsequent hysterectomy [<a href="#rid68">68</a>].</p><p>However, IAL precludes subsequent embolization. Therefore, it should be reserved for patients who are unlikely to be candidates for arterial embolization.</p><p>The technique for IAL is performed bilaterally as follows:</p><p class="bulletIndent1"><span class="glyph">●</span>Open the anterior leaf of the broad ligament (with a Metzenbaum scissors or electrosurgery) and lyse the areolar tissue of the retroperitoneum.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The external iliac artery is readily identified at the medial margin of the psoas muscle, and is followed to the common iliac artery bifurcation. The internal iliac artery is approximately 4 cm in length before it divides into anterior and posterior branches.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Ideally, the dissection should be carried caudally to the anterior and posterior trunks of the internal iliac artery so that the anterior trunk can be selectively ligated. In practice, this is so difficult that the entire internal iliac artery usually is ligated at its origin.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Dissect away the nodal tissue overlying the internal iliac artery by spreading the tissue with a right angle or tonsil clamp or the tips of Metzenbaum scissors. Continue the dissection anterior and lateral to the internal iliac artery. Proceed in the same plane around the circumference of the artery to separate it from the internal iliac vein, which is slightly medial and posterior to the artery. Pass a number 1 silk or nonabsorbable synthetic suture (eg, polypropylene) around the artery from lateral to medial and tie securely. An alternative technique is to use surgical clips to ligate the internal iliac artery, which eliminates the need for circumferential dissection and thus may reduce the risk of iliac vein injury [<a href="#rid69">69</a>]. </p><p></p><p>There are two important technical errors that are easy to commit, both of which may be detrimental:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Ligation of external iliac artery</strong> – It is possible to mistakenly ligate the external iliac instead of the internal iliac artery. This usually leads to loss of the ipsilateral lower limb if not promptly corrected. Therefore, the lower limb (dorsalis pedis, or posterior tibial pulse) should be assessed for the presence of a pulse immediately after vessel ligation.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Injury of iliac veins or external iliac artery</strong> – The large, dilated, fragile internal iliac vein lies just behind and slightly medial to the artery and is often not visualized during isolation of the artery. Laceration of this vein can lead to rapid exsanguination. The external iliac artery lies lateral to the internal iliac artery and care should also be taken to avoid it.</p><p></p><p>A review of pregnancy outcome after internal iliac artery ligation for postpartum hemorrhage described 49 pregnancies with no evidence of any increase in adverse events [<a href="#rid70">70</a>].</p><p class="headingAnchor" id="H15851592"><span class="h3">Uterine artery ligation</span><span class="headingEndMark"> — </span>Mass ligation of the uterine artery may be performed. The arteries are identified by palpation. To ligate the left uterine artery, the uterus is elevated upwards and to the right. A large blunt needle (eg, size 5 Mayo) with #0 or #1 absorbable suture is passed into and through the myometrium approximately 2 cm medial to and below the uterine vessels. The needle is brought out through the avascular area in the broad ligament, cephalad and lateral to left uterine vessels, and the suture is tied. The procedure is repeated on the contralateral side  (<a class="graphic graphic_figure graphicRef83009" href="/d/graphic/83009.html" rel="external">figure 3</a>).</p><p class="headingAnchor" id="H20"><span class="h3">Hysterectomy or oophorectomy</span><span class="headingEndMark"> — </span>If bleeding continues despite conservative measures, removal of the adnexae or uterus may be necessary despite the initial surgical plan. For example, in women undergoing myomectomy or ovarian cystectomy who develop intractable bleeding, the possibility of emergency measures in case of hemorrhage is part of the preoperative consent process. (See  <a class="medical medical_review" href="/d/html/3301.html" rel="external">"Overview of preoperative evaluation and preparation for gynecologic surgery"</a>.)</p><p class="headingAnchor" id="H21"><span class="h3">Prolonged pelvic packing</span><span class="headingEndMark"> — </span>If other measures do not control bleeding, a pressure pack may be left in the pelvis for 48 to 72 hours [<a href="#rid71">71,72</a>]. This is effective for venous bleeding. The patient is monitored closely and appropriate fluid resuscitation and blood transfusion administered in an intensive care setting. Packs may be removed via the vaginal cuff or by re-opening the laparotomy [<a href="#rid65">65,71</a>]. The abdominal incision may be loosely re-approximated so that the incision can be re-opened if needed for persistent bleeding. Our approach to pelvic packing in a patient who had a hysterectomy is as follows [<a href="#rid65">65</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>Fill a large sterile drawstring-closure plastic bag with three rolls of gauze tied end-to-end; leave the tail of the gauze protruding through the bag's opening and tighten the drawstrings. Place the pack is in the pelvis, avoiding bowel or ovary entrapment. Pull the drawstrings and gauze tail through the vaginal cuff. A 1000 mL intravenous fluid bag is attached to the pack with surgical tubing and hung off the end of the bed for traction. Place a Jackson-Pratt drain in the pelvis to monitor for continued bleeding and an indwelling urinary catheter to avoid outflow obstruction and monitor urine output</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>After 48 to 72 hours, if vaginal and Jackson-Pratt drainage have decreased, remove the gauze through the vagina, slowly over four hours. The bag can then be removed through the vagina and the vaginal cuff left open.</p><p></p><p class="headingAnchor" id="H22"><span class="h3">Other measures</span><span class="headingEndMark"> — </span>The use of medical anti-shock trousers or garments is controversial. While a few case reports and a small case series report successful use in gynecologic and obstetric hemorrhage [<a href="#rid73">73-75</a>], an animal study of intraabdominal hemorrhage found that these devices did not slow bleeding [<a href="#rid76">76</a>]. In abdominal myomectomy, a systematic review found that intravenous <a class="drug drug_general" data-topicid="10011" href="/d/drug information/10011.html" rel="external">tranexamic acid</a> (1 mg/kg) given prior to incision significantly reduced intraoperative bleeding (mean -251 mL, 95% CI -391 to -110) [<a href="#rid23">23</a>]. One randomized trial found no significant decrease in transfusion rates with tranexamic acid administered just prior to surgery [<a href="#rid77">77</a>]. However, in the setting of advanced ovarian cancer surgery, a randomized trial showed significantly reduced blood loss and transfusion rates compared with a control group [<a href="#rid78">78</a>].</p><p class="headingAnchor" id="H23"><span class="h1">MEDICAL STABILIZATION</span><span class="headingEndMark"> — </span>As noted above, ongoing communication between the surgeon and anesthesiologist are required to safely manage operative hemorrhage. The need for additional monitoring or placement of lines, and blood replacement products should be addressed at regular intervals. The major nonsurgical components of stabilizing a bleeding patient include:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Hemodynamic monitoring</strong> – (See  <a class="medical medical_review" href="/d/html/2298.html" rel="external">"Etiology, clinical manifestations, and diagnosis of volume depletion in adults"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Fluid and electrolyte management</strong> – A general rule of fluid replacement for hemorrhage is a 3:1 ratio of crystalloid fluid to blood loss [<a href="#rid79">79</a>]. A full discussion of crystalloid versus colloid solutions is found separately. (See  <a class="medical medical_review" href="/d/html/1607.html" rel="external">"Treatment of severe hypovolemia or hypovolemic shock in adults"</a> and  <a class="medical medical_review" href="/d/html/2296.html" rel="external">"Maintenance and replacement fluid therapy in adults"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Blood product replacement</strong> – Transfusion during perioperative hemorrhage often requires replacement of red blood cell and plasma components  (<a class="graphic graphic_table graphicRef53854" href="/d/graphic/53854.html" rel="external">table 4</a>). Disseminated intravascular coagulation (DIC) is of particular concern in a patient with major blood loss  (<a class="graphic graphic_table graphicRef63831" href="/d/graphic/63831.html" rel="external">table 5</a>). (See  <a class="medical medical_review" href="/d/html/7931.html" rel="external">"Massive blood transfusion"</a> and  <a class="medical medical_review" href="/d/html/1306.html" rel="external">"Evaluation and management of disseminated intravascular coagulation (DIC) in adults"</a> and  <a class="medical medical_review" href="/d/html/7920.html" rel="external">"Clinical use of plasma components"</a>.)</p><p></p><p class="headingAnchor" id="H24"><span class="h1">POSTOPERATIVE BLEEDING</span><span class="headingEndMark"> — </span>Careful inspection of all pedicles before abdominal closure is the best method to prevent postoperative hemorrhage.</p><p class="headingAnchor" id="H25"><span class="h2">Clinical manifestations</span><span class="headingEndMark"> — </span>Tachycardia, hypotension, oliguria (urine output &lt;20 mL/hour), confusion, and increasing abdominal pain may all signal postoperative intraabdominal bleeding.</p><p>Postoperative hemorrhage may be plainly visible, in the case of bleeding from the vagina or wound, otherwise, intraabdominal bleeding should be suspected.</p><p>Patients who undergo laparoscopic surgery may also present approximately 72 hours postoperatively with a drop in hemoglobin and a large purplish discoloration or hematoma of a lower quadrant of the abdomen, ipsilateral flank, or in the groin, dissecting down to the ipsilateral labia majora. A computed tomography (CT) scan will reveal a large hematoma within the abdominal wall, which may extend along muscle planes to the flank. The discoloration will resolve over 10 to 14 days as the blood is absorbed. Presumably, a vessel in the anterior abdominal wall was injured, went into spasm, and then relaxed and bled at a later time until it became tamponaded. These patients do not have pain or discomfort.</p><p class="headingAnchor" id="H26"><span class="h2">Evaluation</span><span class="headingEndMark"> — </span>Evaluation of a patient with suspected postoperative bleeding includes physical examination and assessment of vital signs and urine output. A laboratory evaluation should exclude a decreasing Hct or bleeding diathesis. Of note, postoperative mobilization of fluids from the extravascular space can lead to a falling Hct level without ongoing bleeding.</p><p>The patient should be taken promptly to the examining room where the operative site is inspected (including the vaginal cuff if the patient has had a hysterectomy).</p><p class="headingAnchor" id="H27"><span class="h2">Management</span><span class="headingEndMark"> — </span>If there is suspicion of postoperative hemorrhage, fluid resuscitation should be initiated and preparation made for possible surgical re-exploration. Large-bore intravenous access should be placed, isotonic fluids given (normal <a class="drug drug_general" data-topicid="9929" href="/d/drug information/9929.html" rel="external">saline</a> or Ringers lactate), the Foley catheter reinserted, and the patient maintained nil per os (npo). As noted above, crystalloid fluids should be replaced in a 3:1 ratio of fluid to blood loss.</p><p>Bleeding from the vaginal cuff can usually be sutured in the examination room. Likewise, superficial bleeding from wound can be controlled by opening the wound and coagulating or suturing subcutaneous vessels.</p><p>Patients who are stable but anemic may be managed conservatively. Transfusion is given, if appropriate, and hemodynamic status, urine output, and Hct are monitored. Further evaluation and more aggressive management are indicated if there is suspicion of ongoing blood loss.</p><p class="headingAnchor" id="H28"><span class="h3">Surgical re-exploration</span><span class="headingEndMark"> — </span>Patients who are hemodynamically unstable or have an increasing abdominal girth should be surgically re-explored. Identification of bleeding source and control of bleeding proceeds as described above. (See <a class="local">'Management of intraoperative bleeding'</a> above.)</p><p>Abdominal compartment syndrome can be caused by significant intraperitoneal or retroperitoneal bleeding resulting in raised intraabdominal pressure. The increased pressure can be transmitted to the pleural space causing a decrease in lung compliance and hypoxemia and a decrease in venous return. Decreased perfusion of the kidneys can lead to oliguria and renal failure. CT is useful to assess the location and amount of intra- or retroperitoneal blood collection. (See  <a class="medical medical_review" href="/d/html/2889.html" rel="external">"Abdominal compartment syndrome in adults"</a>.)</p><p class="headingAnchor" id="H29"><span class="h3">Embolization</span><span class="headingEndMark"> — </span>Embolization is typically performed by interventional radiologists and halts pelvic bleeding by occluding pelvic arteries. This is an option for patients in whom volume status can be maintained until the procedure can be completed (approximately two hours). As discussed above, ligation of the internal iliac artery will preclude subsequent embolization. </p><p>Preoperative embolization has been used for procedures where the risk of hemorrhage is felt to be high. </p><p class="headingAnchor" id="H30"><span class="h3">Endografts</span><span class="headingEndMark"> — </span>Patients with postoperative bleeding due to injury to the vena cava or common or external iliac veins may be candidates for placement of stented grafts by an endovascular specialist. (See  <a class="medical medical_review" href="/d/html/15203.html" rel="external">"Endovascular repair of abdominal aortic aneurysm"</a>.) </p><p class="headingAnchor" id="H1513796829"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/d/html/122885.html" rel="external">"Society guideline links: Gynecologic surgery"</a>.)</p><p class="headingAnchor" id="H31"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Definition of hemorrhage</strong> – Intraoperative hemorrhage is typically defined as ≥1000 mL blood loss; massive hemorrhage refers to acute blood loss of ≥25 percent of a patient's blood volume or bleeding that requires emergency intervention to save the patient's life. (See <a class="local">'Introduction'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Preoperative evaluation for bleeding diathesis</strong> – Prior to surgery, if a bleeding diathesis is suspected based on personal or family history or medication use, evaluation by a hematologist is indicated. Nongynecologic etiologies of bleeding symptoms may be present. As an example, menorrhagia, a common indication for gynecologic surgery, can be a presenting symptom of von Willebrand disease (VWD). (See <a class="local">'Preoperative evaluation'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Approach to preoperative patient anemia</strong> </p><p></p><p class="bulletIndent2"><span class="glyph">•</span>In women who are unwilling to accept perioperative blood transfusion and who are anemic despite standard therapy (replacement of iron; attempts to control AUB), we suggest preoperative erythropoietic agents (<a class="grade" href="https://medilib.ir/uptodate/show/grade_6" rel="external">Grade 2C</a>). (See <a class="local">'Correction of anemia'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Autologous blood donation and intraoperative blood salvage are also options to decrease risk of transmission of blood borne infection and transfusion reactions. (See  <a class="medical medical_review" href="/d/html/7930.html" rel="external">"Surgical blood conservation: Preoperative autologous blood donation"</a> and  <a class="medical medical_review" href="/d/html/7937.html" rel="external">"Surgical blood conservation: Intraoperative blood salvage"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Approach to intraoperative hemorrhage</strong> </p><p></p><p class="bulletIndent2"><span class="glyph">•</span>The initial steps are to apply pressure and communicate with the surgical team to formulate a plan of action. (See <a class="local">'Management of intraoperative bleeding'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>If initial attempts to decrease bleeding are not successful, the next step is to decrease pelvic blood flow. Bilateral internal iliac (hypogastric) artery ligation (IAL) lowers the pulse pressure of the pelvic vasculature, making clot formation more likely. (See <a class="local">'Internal iliac artery ligation'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Diffuse bleeding from all operative and vascular access sites requires evaluation for disseminated intravascular coagulation. (See <a class="local">'Medical stabilization'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Techniques to control intraoperative bleeding</strong></p><p></p><p class="bulletIndent2"><span class="glyph">•</span>In women undergoing gynecologic surgery with areas of low-volume bleeding, we suggest the use of topical hemostatic agents (<a class="grade" href="https://medilib.ir/uptodate/show/grade_6" rel="external">Grade 2C</a>). (See <a class="local">'Topical hemostatic agents'</a> above.)</p><p></p><p class="bulletIndent2">In the absence of high-quality data, in general, surgeons should pick the topical agent with which they are most familiar. If the choice is to use a combination of gelatin and thrombin, we recommend the combined liquid preparation rather than gelatin sponge soaked in thrombin (<a class="grade" href="https://medilib.ir/uptodate/show/grade_1" rel="external">Grade 1A</a>).</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>If bleeding persists despite conservative measures, IAL, oophorectomy, or hysterectomy may be indicated. In a patient who continues to bleed despite hysterectomy, pelvic packs may be placed and removed in 48 to 72 hours. (See <a class="local">'Prolonged pelvic packing'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Postoperative bleeding</strong> – Patients with postoperative bleeding who are hemodynamically unstable require surgical re-exploration. (See <a class="local">'Postoperative bleeding'</a> above.)</p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Harris WJ. Early complications of abdominal and vaginal hysterectomy. Obstet Gynecol Surv 1995; 50:795.</a></li><li><a class="nounderline abstract_t">Santoso JT, Saunders BA, Grosshart K. Massive blood loss and transfusion in obstetrics and gynecology. Obstet Gynecol Surv 2005; 60:827.</a></li><li><a class="nounderline abstract_t">Carson JL, Noveck H, Berlin JA, Gould SA. Mortality and morbidity in patients with very low postoperative Hb levels who decline blood transfusion. Transfusion 2002; 42:812.</a></li><li><a class="nounderline abstract_t">Smetana GW, Macpherson DS. The case against routine preoperative laboratory testing. Med Clin North Am 2003; 87:7.</a></li><li><a class="nounderline abstract_t">Ransom SB, McNeeley SG, Hosseini RB. Cost-effectiveness of routine blood type and screen testing before elective laparoscopy. Obstet Gynecol 1995; 86:346.</a></li><li><a class="nounderline abstract_t">Ransom SB, McNeeley SG, Malone JM Jr. A cost-effectiveness evaluation of preoperative type-and-screen testing for vaginal hysterectomy. Am J Obstet Gynecol 1996; 175:1201.</a></li><li><a class="nounderline abstract_t">James AH, Ragni MV, Picozzi VJ. Bleeding disorders in premenopausal women: (another) public health crisis for hematology? Hematology Am Soc Hematol Educ Program 2006; :474.</a></li><li><a class="nounderline abstract_t">Muñoz M, Naveira E, Seara J, et al. Role of parenteral iron in transfusion requirements after total hip replacement. A pilot study. Transfus Med 2006; 16:137.</a></li><li><a class="nounderline abstract_t">Shander A, Spence RK, Auerbach M. Can intravenous iron therapy meet the unmet needs created by the new restrictions on erythropoietic stimulating agents? Transfusion 2010; 50:719.</a></li><li><a class="nounderline abstract_t">Sesti F, Ticconi C, Bonifacio S, Piccione E. Preoperative administration of recombinant human erythropoietin in patients undergoing gynecologic surgery. Gynecol Obstet Invest 2002; 54:1.</a></li><li><a class="nounderline abstract_t">Wurnig C, Schatz K, Noske H, et al. Subcutaneous low-dose epoetin beta for the avoidance of transfusion in patients scheduled for elective surgery not eligible for autologous blood donation. Eur Surg Res 2001; 33:303.</a></li><li><a class="nounderline abstract_t">Weber EW, Slappendel R, Hémon Y, et al. Effects of epoetin alfa on blood transfusions and postoperative recovery in orthopaedic surgery: the European Epoetin Alfa Surgery Trial (EEST). Eur J Anaesthesiol 2005; 22:249.</a></li><li><a class="nounderline abstract_t">Feagan BG, Wong CJ, Kirkley A, et al. Erythropoietin with iron supplementation to prevent allogeneic blood transfusion in total hip joint arthroplasty. A randomized, controlled trial. Ann Intern Med 2000; 133:845.</a></li><li><a class="nounderline abstract_t">Faris P. Use of recombinant human erythropoietin in the perioperative period of orthopedic surgery. Am J Med 1996; 101:28S.</a></li><li><a class="nounderline abstract_t">Goldberg MA, McCutchen JW, Jove M, et al. A safety and efficacy comparison study of two dosing regimens of epoetin alfa in patients undergoing major orthopedic surgery. Am J Orthop (Belle Mead NJ) 1996; 25:544.</a></li><li><a class="nounderline abstract_t">D'Ambra MN, Gray RJ, Hillman R, et al. Effect of recombinant human erythropoietin on transfusion risk in coronary bypass patients. Ann Thorac Surg 1997; 64:1686.</a></li><li class="breakAll">http://www.fda.gov/medwatch/safety/2008/safety08.htm#ESA (Accessed on June 03, 2008).</li><li><a class="nounderline abstract_t">Karger, R. The cost-effectiveness of autologous transfusion alternatives: an update and reappraisal. Transfusion Alternatives in Transfusion Medicine 2007; 9:91.</a></li><li><a class="nounderline abstract_t">West S, Ruiz R, Parker WH. Abdominal myomectomy in women with very large uterine size. Fertil Steril 2006; 85:36.</a></li><li><a class="nounderline abstract_t">Yamada T, Ikeda A, Okamoto Y, et al. Intraoperative blood salvage in abdominal simple total hysterectomy for uterine myoma. Int J Gynaecol Obstet 1997; 59:233.</a></li><li><a class="nounderline abstract_t">American Society of Anesthesiologists Task Force on Perioperative Blood Transfusion and Adjuvant Therapies. Practice guidelines for perioperative blood transfusion and adjuvant therapies: an updated report by the American Society of Anesthesiologists Task Force on Perioperative Blood Transfusion and Adjuvant Therapies. Anesthesiology 2006; 105:198.</a></li><li><a class="nounderline abstract_t">Kongnyuy EJ, Wiysonge CS. Interventions to reduce haemorrhage during myomectomy for fibroids. Cochrane Database Syst Rev 2014; :CD005355.</a></li><li><a class="nounderline abstract_t">Topsoee MF, Settnes A, Ottesen B, Bergholt T. A systematic review and meta-analysis of the effect of prophylactic tranexamic acid treatment in major benign uterine surgery. Int J Gynaecol Obstet 2017; 136:120.</a></li><li><a class="nounderline abstract_t">Lakshmi SD, Abraham R. Role of Prophylactic Tranexamic Acid in Reducing Blood Loss during Elective Caesarean Section: A Randomized Controlled Study. J Clin Diagn Res 2016; 10:QC17.</a></li><li><a class="nounderline abstract_t">Devereaux PJ, Marcucci M, Painter TW, et al. Tranexamic Acid in Patients Undergoing Noncardiac Surgery. N Engl J Med 2022; 386:1986.</a></li><li><a class="nounderline abstract_t">Maslovitz S, Barkai G, Lessing JB, et al. Recurrent obstetric management mistakes identified by simulation. Obstet Gynecol 2007; 109:1295.</a></li><li><a class="nounderline abstract_t">Deering SH, Chinn M, Hodor J, et al. Use of a postpartum hemorrhage simulator for instruction and evaluation of residents. J Grad Med Educ 2009; 1:260.</a></li><li><a class="nounderline abstract_t">Huser AS, Müller D, Brunkhorst V, et al. Simulated life-threatening emergency during robot-assisted surgery. J Endourol 2014; 28:717.</a></li><li><a class="nounderline abstract_t">Akdemir A, Sendağ F, Oztekin MK. Laparoscopic virtual reality simulator and box trainer in gynecology. Int J Gynaecol Obstet 2014; 125:181.</a></li><li><a class="nounderline abstract_t">Tunitsky-Bitton E, King CR, Ridgeway B, et al. Development and validation of a laparoscopic sacrocolpopexy simulation model for surgical training. J Minim Invasive Gynecol 2014; 21:612.</a></li><li><a class="nounderline abstract_t">Gostout BS, Cliby WA, Podratz KC. Prevention and management of acute intraoperative bleeding. Clin Obstet Gynecol 2002; 45:481.</a></li><li><a class="nounderline abstract_t">Duenas-Garcia OF, Goldberg JM. Topical hemostatic agents in gynecologic surgery. Obstet Gynecol Surv 2008; 63:389.</a></li><li><a class="nounderline abstract_t">Achneck HE, Sileshi B, Jamiolkowski RM, et al. A comprehensive review of topical hemostatic agents: efficacy and recommendations for use. Ann Surg 2010; 251:217.</a></li><li><a class="nounderline abstract_t">Gabay M. Absorbable hemostatic agents. Am J Health Syst Pharm 2006; 63:1244.</a></li><li><a class="nounderline abstract_t">Berrevoet F, de Hemptinne B. Use of topical hemostatic agents during liver resection. Dig Surg 2007; 24:288.</a></li><li><a class="nounderline abstract_t">Topical Hemostatic Agents at Time of Obstetric and Gynecologic Surgery: ACOG Committee Opinion, Number 812. Obstet Gynecol 2020.</a></li><li><a class="nounderline abstract_t">Stachowicz AM, Whiteside JL. Topical Hemostatic Agents in Gynecologic Surgery for Benign Indications. Obstet Gynecol 2020; 135:463.</a></li><li><a class="nounderline abstract_t">American College of Obstetricians and Gynecologists’ Committee on Gynecologic Practice. Topical Hemostatic Agents at Time of Obstetric and Gynecologic Surgery: ACOG Committee Opinion, Number 812. Obstet Gynecol 2020; 136:e81.</a></li><li><a class="nounderline abstract_t">Hong YM, Loughlin KR. The use of hemostatic agents and sealants in urology. J Urol 2006; 176:2367.</a></li><li><a class="nounderline abstract_t">Weaver FA, Hood DB, Zatina M, et al. Gelatin-thrombin-based hemostatic sealant for intraoperative bleeding in vascular surgery. Ann Vasc Surg 2002; 16:286.</a></li><li><a class="nounderline abstract_t">Mannucci PM. Hemostatic drugs. N Engl J Med 1998; 339:245.</a></li><li><a class="nounderline abstract_t">Wiseman DM, Kamp LF, Saferstein L, et al. Improving the efficacy of INTERCEED Barrier in the presence of blood using thrombin, heparin or a blood insensitive barrier, modified INTERCEED (nTC7). Prog Clin Biol Res 1993; 381:205.</a></li><li><a class="nounderline abstract_t">Sharma JB, Malhotra M, Pundir P. Laparoscopic oxidized cellulose (Surgicel) application for small uterine perforations. Int J Gynaecol Obstet 2003; 83:271.</a></li><li><a class="nounderline abstract_t">Sharma JB, Malhotra M. Topical oxidized cellulose for tubal hemorrhage hemostasis during laparoscopic sterilization. Int J Gynaecol Obstet 2003; 82:221.</a></li><li><a class="nounderline abstract_t">Kitamura K, Yasuoka R, Ohara M, et al. How safe are the xenogeneic hemostats?--Report of a case of severe systemic allergic reaction. Surg Today 1995; 25:433.</a></li><li><a class="nounderline abstract_t">Borten M, Friedman EA. Translaparoscopic hemostasis with microfibrillar collagen in lieu of laparotomy. A report of two cases. J Reprod Med 1983; 28:804.</a></li><li><a class="nounderline abstract_t">Holub Z, Jabor A. Laparoscopic management of bleeding after laparoscopic or vaginal hysterectomy. JSLS 2004; 8:235.</a></li><li><a class="nounderline abstract_t">Nakajima M, Kamei T, Tomimatu K, Manabe T. An intraperitoneal tumorous mass caused by granulomas of microfibrillar collagen hemostat (Avitene). Arch Pathol Lab Med 1995; 119:1161.</a></li><li><a class="nounderline abstract_t">Rousou J, Levitsky S, Gonzalez-Lavin L, et al. Randomized clinical trial of fibrin sealant in patients undergoing resternotomy or reoperation after cardiac operations. A multicenter study. J Thorac Cardiovasc Surg 1989; 97:194.</a></li><li><a class="nounderline abstract_t">Lawson JH. The clinical use and immunologic impact of thrombin in surgery. Semin Thromb Hemost 2006; 32 Suppl 1:98.</a></li><li class="breakAll">Thrombin, topical-bovine kit. US Food and Drug Administration (FDA) approved product information. Revised October 28, 2022. US National Library of Medicine. https://www.dailymed.nlm.nih.gov/ (Accessed on June 21, 2023).</li><li><a class="nounderline abstract_t">Weaver FA, Lew W, Granke K, et al. A comparison of recombinant thrombin to bovine thrombin as a hemostatic ancillary in patients undergoing peripheral arterial bypass and arteriovenous graft procedures. J Vasc Surg 2008; 47:1266.</a></li><li><a class="nounderline abstract_t">Chapman WC, Singla N, Genyk Y, et al. A phase 3, randomized, double-blind comparative study of the efficacy and safety of topical recombinant human thrombin and bovine thrombin in surgical hemostasis. J Am Coll Surg 2007; 205:256.</a></li><li><a class="nounderline abstract_t">Schoenecker JG, Johnson RK, Fields RC, et al. Relative purity of thrombin-based hemostatic agents used in surgery. J Am Coll Surg 2003; 197:580.</a></li><li><a class="nounderline abstract_t">Adams JD, Jones S, Brost BC. Development of antibodies to topical bovine thrombin after abdominal hysterectomy. A case report. J Reprod Med 2001; 46:909.</a></li><li><a class="nounderline abstract_t">Morita Y, Nishii O, Kido M, Tsutsumi O. Parvovirus infection after laparoscopic hysterectomy using fibrin glue hemostasis. Obstet Gynecol 2000; 95:1026.</a></li><li><a class="nounderline abstract_t">Raga F, Sanz-Cortes M, Bonilla F, et al. Reducing blood loss at myomectomy with use of a gelatin-thrombin matrix hemostatic sealant. Fertil Steril 2009; 92:356.</a></li><li><a class="nounderline abstract_t">Han LY, Schimp V, Oh JC, Ramirez PT. A gelatin matrix-thrombin tissue sealant (FloSeal) application in the management of groin breakdown after inguinal lymphadenectomy for vulvar cancer. Int J Gynecol Cancer 2004; 14:621.</a></li><li><a class="nounderline abstract_t">Renkens KL Jr, Payner TD, Leipzig TJ, et al. A multicenter, prospective, randomized trial evaluating a new hemostatic agent for spinal surgery. Spine (Phila Pa 1976) 2001; 26:1645.</a></li><li><a class="nounderline abstract_t">Oz MC, Cosgrove DM 3rd, Badduke BR, et al. Controlled clinical trial of a novel hemostatic agent in cardiac surgery. The Fusion Matrix Study Group. Ann Thorac Surg 2000; 69:1376.</a></li><li><a class="nounderline abstract_t">Hanks JB, Kjaergard HK, Hollingsbee DA. A comparison of the haemostatic effect of Vivostat patient-derived fibrin sealant with oxidised cellulose (Surgicel) in multiple surgical procedures. Eur Surg Res 2003; 35:439.</a></li><li><a class="nounderline abstract_t">Kumar S, Malhotra N, Chumber S, et al. Control of presacral venous bleeding, using thumbtacks. Arch Gynecol Obstet 2007; 276:385.</a></li><li><a class="nounderline abstract_t">Wydra D, Emerich J, Ciach K, Marciniak A. Management of massive presacral pelvic bleeding in patients with gynecological malignances: review of the literature. Eur J Gynaecol Oncol 2005; 26:151.</a></li><li><a class="nounderline abstract_t">Harrison JL, Hooks VH, Pearl RK, et al. Muscle fragment welding for control of massive presacral bleeding during rectal mobilization: a review of eight cases. Dis Colon Rectum 2003; 46:1115.</a></li><li><a class="nounderline abstract_t">Howard RJ, Straughn JM Jr, Huh WK, Rouse DJ. Pelvic umbrella pack for refractory obstetric hemorrhage secondary to posterior uterine rupture. Obstet Gynecol 2002; 100:1061.</a></li><li><a class="nounderline abstract_t">Burchell RC. Physiology of internal iliac artery ligation. J Obstet Gynaecol Br Commonw 1968; 75:642.</a></li><li><a class="nounderline abstract_t">Evans S, McShane P. The efficacy of internal iliac artery ligation in obstetric hemorrhage. Surg Gynecol Obstet 1985; 160:250.</a></li><li><a class="nounderline abstract_t">Clark SL, Phelan JP, Yeh SY, et al. Hypogastric artery ligation for obstetric hemorrhage. Obstet Gynecol 1985; 66:353.</a></li><li><a class="nounderline abstract_t">Sanders AP, Hobson SR, Kobylianskii A, et al. Internal iliac artery ligation-a contemporary simplified approach. Am J Obstet Gynecol 2021; 225:339.</a></li><li><a class="nounderline abstract_t">Nizard J, Barrinque L, Frydman R, Fernandez H. Fertility and pregnancy outcomes following hypogastric artery ligation for severe post-partum haemorrhage. Hum Reprod 2003; 18:844.</a></li><li><a class="nounderline abstract_t">Tamizian O, Arulkumaran S. The surgical management of postpartum haemorrhage. Curr Opin Obstet Gynecol 2001; 13:127.</a></li><li><a class="nounderline abstract_t">Finan MA, Fiorica JV, Hoffman MS, et al. Massive pelvic hemorrhage during gynecologic cancer surgery: "pack and go back". Gynecol Oncol 1996; 62:390.</a></li><li><a class="nounderline abstract_t">Hauswald M. Uncontrollable intraabdominal hemorrhage treated with packing and use of a MAST suit. J Reprod Med 1987; 32:68.</a></li><li><a class="nounderline abstract_t">Guerre EF Jr, O'Keeffe DF, Elliott JP, et al. Uncontrollable intraabdominal hemorrhage treated with packing and use of a MAST suit. A case report. J Reprod Med 1987; 32:230.</a></li><li><a class="nounderline abstract_t">Hensleigh PA. Anti-shock garment provides resuscitation and haemostasis for obstetric haemorrhage. BJOG 2002; 109:1377.</a></li><li><a class="nounderline abstract_t">Low RB, Schmidt C, Wilder RJ, et al. Control of intraabdominal hemorrhage and shock: a comparison of fluid resuscitation, MAST, and balloon occlusion. Ann Emerg Med 1985; 14:540.</a></li><li><a class="nounderline abstract_t">Caglar GS, Tasci Y, Kayikcioglu F, Haberal A. Intravenous tranexamic acid use in myomectomy: a prospective randomized double-blind placebo controlled study. Eur J Obstet Gynecol Reprod Biol 2008; 137:227.</a></li><li><a class="nounderline abstract_t">Lundin ES, Johansson T, Zachrisson H, et al. Single-dose tranexamic acid in advanced ovarian cancer surgery reduces blood loss and transfusions: double-blind placebo-controlled randomized multicenter study. Acta Obstet Gynecol Scand 2014; 93:335.</a></li><li class="breakAll">Spann, CO. Water, electrolyte, and acid-base metabolism. In: TeLinde's Operative Gynecology, 8th ed, Rock JA, Thompson JD (Eds), Lippincott Williams &amp; Wilkins, Philadelphia 1997. p.165.</li></ol></div><div id="topicVersionRevision">Topic 3302 Version 34.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8545085" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Early complications of abdominal and vaginal hysterectomy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16359565" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Massive blood loss and transfusion in obstetrics and gynecology.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12375651" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Mortality and morbidity in patients with very low postoperative Hb levels who decline blood transfusion.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12575882" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : The case against routine preoperative laboratory testing.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7651640" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Cost-effectiveness of routine blood type and screen testing before elective laparoscopy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8942488" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : A cost-effectiveness evaluation of preoperative type-and-screen testing for vaginal hysterectomy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17124102" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Bleeding disorders in premenopausal women: (another) public health crisis for hematology?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16623920" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Role of parenteral iron in transfusion requirements after total hip replacement. A pilot study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19919555" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Can intravenous iron therapy meet the unmet needs created by the new restrictions on erythropoietic stimulating agents?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12297709" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Preoperative administration of recombinant human erythropoietin in patients undergoing gynecologic surgery.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11805389" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Subcutaneous low-dose epoetin beta for the avoidance of transfusion in patients scheduled for elective surgery not eligible for autologous blood donation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15892401" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Effects of epoetin alfa on blood transfusions and postoperative recovery in orthopaedic surgery: the European Epoetin Alfa Surgery Trial (EEST).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11103054" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Erythropoietin with iron supplementation to prevent allogeneic blood transfusion in total hip joint arthroplasty. A randomized, controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8928705" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Use of recombinant human erythropoietin in the perioperative period of orthopedic surgery.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8871752" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : A safety and efficacy comparison study of two dosing regimens of epoetin alfa in patients undergoing major orthopedic surgery.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9436556" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Effect of recombinant human erythropoietin on transfusion risk in coronary bypass patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9436556" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Effect of recombinant human erythropoietin on transfusion risk in coronary bypass patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : The cost-effectiveness of autologous transfusion alternatives: an update and reappraisal</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16412723" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Abdominal myomectomy in women with very large uterine size.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9486513" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Intraoperative blood salvage in abdominal simple total hysterectomy for uterine myoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16810012" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Practice guidelines for perioperative blood transfusion and adjuvant therapies: an updated report by the American Society of Anesthesiologists Task Force on Perioperative Blood Transfusion and Adjuvant Therapies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25125317" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Interventions to reduce haemorrhage during myomectomy for fibroids.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28099726" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : A systematic review and meta-analysis of the effect of prophylactic tranexamic acid treatment in major benign uterine surgery.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28208943" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Role of Prophylactic Tranexamic Acid in Reducing Blood Loss during Elective Caesarean Section: A Randomized Controlled Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35363452" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Tranexamic Acid in Patients Undergoing Noncardiac Surgery.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17540800" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Recurrent obstetric management mistakes identified by simulation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21975989" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Use of a postpartum hemorrhage simulator for instruction and evaluation of residents.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24471449" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Simulated life-threatening emergency during robot-assisted surgery.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24576509" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Laparoscopic virtual reality simulator and box trainer in gynecology.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24462591" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Development and validation of a laparoscopic sacrocolpopexy simulation model for surgical training.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12048406" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Prevention and management of acute intraoperative bleeding.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18492295" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Topical hemostatic agents in gynecologic surgery.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20010084" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : A comprehensive review of topical hemostatic agents: efficacy and recommendations for use.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16790576" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Absorbable hemostatic agents.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17657154" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Use of topical hemostatic agents during liver resection.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Topical Hemostatic Agents at Time of Obstetric and Gynecologic Surgery: ACOG Committee Opinion, Number 812</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31923069" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Topical Hemostatic Agents in Gynecologic Surgery for Benign Indications.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32976379" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Topical Hemostatic Agents at Time of Obstetric and Gynecologic Surgery: ACOG Committee Opinion, Number 812.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17085103" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : The use of hemostatic agents and sealants in urology.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11957004" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Gelatin-thrombin-based hemostatic sealant for intraoperative bleeding in vascular surgery.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9673304" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Hemostatic drugs.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8316564" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Improving the efficacy of INTERCEED Barrier in the presence of blood using thrombin, heparin or a blood insensitive barrier, modified INTERCEED (nTC7).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14643037" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Laparoscopic oxidized cellulose (Surgicel) application for small uterine perforations.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12873787" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : Topical oxidized cellulose for tubal hemorrhage hemostasis during laparoscopic sterilization.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7640472" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : How safe are the xenogeneic hemostats?--Report of a case of severe systemic allergic reaction.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6228653" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : Translaparoscopic hemostasis with microfibrillar collagen in lieu of laparotomy. A report of two cases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15347110" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : Laparoscopic management of bleeding after laparoscopic or vaginal hysterectomy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7503666" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : An intraperitoneal tumorous mass caused by granulomas of microfibrillar collagen hemostat (Avitene).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2464722" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : Randomized clinical trial of fibrin sealant in patients undergoing resternotomy or reoperation after cardiac operations. A multicenter study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16673271" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : The clinical use and immunologic impact of thrombin in surgery.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16673271" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : The clinical use and immunologic impact of thrombin in surgery.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18440754" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : A comparison of recombinant thrombin to bovine thrombin as a hemostatic ancillary in patients undergoing peripheral arterial bypass and arteriovenous graft procedures.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17660072" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : A phase 3, randomized, double-blind comparative study of the efficacy and safety of topical recombinant human thrombin and bovine thrombin in surgical hemostasis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14522327" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : Relative purity of thrombin-based hemostatic agents used in surgery.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11725736" id="rid54" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>55 : Development of antibodies to topical bovine thrombin after abdominal hysterectomy. A case report.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10808014" id="rid55" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>56 : Parvovirus infection after laparoscopic hysterectomy using fibrin glue hemostasis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19423098" id="rid56" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>57 : Reducing blood loss at myomectomy with use of a gelatin-thrombin matrix hemostatic sealant.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15304156" id="rid57" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>58 : A gelatin matrix-thrombin tissue sealant (FloSeal) application in the management of groin breakdown after inguinal lymphadenectomy for vulvar cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11474348" id="rid58" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>59 : A multicenter, prospective, randomized trial evaluating a new hemostatic agent for spinal surgery.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10881808" id="rid59" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>60 : Controlled clinical trial of a novel hemostatic agent in cardiac surgery. The Fusion Matrix Study Group.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12928602" id="rid60" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>61 : A comparison of the haemostatic effect of Vivostat patient-derived fibrin sealant with oxidised cellulose (Surgicel) in multiple surgical procedures.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17347833" id="rid61" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>62 : Control of presacral venous bleeding, using thumbtacks.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15857018" id="rid62" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>63 : Management of massive presacral pelvic bleeding in patients with gynecological malignances: review of the literature.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12907909" id="rid63" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>64 : Muscle fragment welding for control of massive presacral bleeding during rectal mobilization: a review of eight cases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12423804" id="rid64" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>65 : Pelvic umbrella pack for refractory obstetric hemorrhage secondary to posterior uterine rupture.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/5659060" id="rid65" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>66 : Physiology of internal iliac artery ligation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3871975" id="rid66" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>67 : The efficacy of internal iliac artery ligation in obstetric hemorrhage.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3875064" id="rid67" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>68 : Hypogastric artery ligation for obstetric hemorrhage.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34097908" id="rid68" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>69 : Internal iliac artery ligation-a contemporary simplified approach.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12660282" id="rid69" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>70 : Fertility and pregnancy outcomes following hypogastric artery ligation for severe post-partum haemorrhage.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11315865" id="rid70" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>71 : The surgical management of postpartum haemorrhage.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8812538" id="rid71" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>72 : Massive pelvic hemorrhage during gynecologic cancer surgery: "pack and go back".</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3498837" id="rid72" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>73 : Uncontrollable intraabdominal hemorrhage treated with packing and use of a MAST suit.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3494843" id="rid73" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>74 : Uncontrollable intraabdominal hemorrhage treated with packing and use of a MAST suit. A case report.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12504974" id="rid74" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>75 : Anti-shock garment provides resuscitation and haemostasis for obstetric haemorrhage.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3994077" id="rid75" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>76 : Control of intraabdominal hemorrhage and shock: a comparison of fluid resuscitation, MAST, and balloon occlusion.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17499419" id="rid76" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>77 : Intravenous tranexamic acid use in myomectomy: a prospective randomized double-blind placebo controlled study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24428857" id="rid77" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>78 : Single-dose tranexamic acid in advanced ovarian cancer surgery reduces blood loss and transfusions: double-blind placebo-controlled randomized multicenter study.</p>
</a>
</div>
</div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
